secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001636282-24-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end
--------------------------------------------------------------------------------

- Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.
- R&D expenses increased to $32.6M (vs $17.4M) driven by IBD pipeline advancement; no acquired IPR&D in Q2 2024.
- SPY001 (anti-α4β7) Phase 1 dosing initiated; interim proof-of-concept data expected by end of 2024 for every-8-12 week dosing.
- SPY002 (anti-TL1A) two candidates with subnanomolar potency; FIH trials in H2 2024 with interim data in H1 2025.
- SPY003 (anti-IL-23) development candidate nominated; FIH trial expected in H1 2025; $426M cash runway into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000053/0001636282-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000053/syre-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001636282-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer